Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.36 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634465 | 1.00 | LMNA (0.43) | LMNAHPGDCYP2C9DGAT2MGAT2 | |
| SCHEMBL1634491 | 1.00 | LMNA (0.43) | LMNAHPGDCYP2C9DGAT2MGAT2 | |
| SCHEMBL1635847 | 1.00 | LMNA (0.43) | LMNAHPGDCYP2C9DGAT2MGAT2 | |
| SCHEMBL1635905 | 0.77 | LMNA (0.44) | LMNAHPGDCYP2C9DGAT2MGAT2 | |
| SCHEMBL1634885 | 0.77 | LMNA (0.44) | LMNAHPGDCYP2C9DGAT2MGAT2 | |
| SCHEMBL1634898 | 0.75 | MME (0.42) | LMNAHPGDCYP2C9DGAT2MGAT2 | |
| SCHEMBL1634705 | 0.75 | MME (0.42) | LMNAHPGDCYP2C9DGAT2MGAT2 | |
| SCHEMBL1635257 | 0.75 | MME (0.42) | LMNAHPGDCYP2C9DGAT2MGAT2 | |
| SCHEMBL1634966 | 0.73 | CYP2C9 (0.37) | LMNAHPGDCYP2C9DGAT2MGAT2 | |
| SCHEMBL1633726 | 0.73 | CYP2C9 (0.37) | LMNAHPGDCYP2C9DGAT2MGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932245-B2 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES (US) | 2011-04-26 | — | — | US | claimed |
| EP-1558230-B1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | claimed |
| EP-1558230-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2005-08-03 | — | — | EP | claimed |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBVIE INC. | 2004-10-14 | — | — | US | claimed |
| WO-2004037240-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
| US-7932245-B2 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES (US) | 2011-04-26 | — | — | US | disclosed |
| EP-1558230-B1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1558230-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBVIE INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004037240-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | SCN1A, SCN1B, SCN10A | LMNA 1139/4885HPGD 593/4885CYP2C9 770/4885 |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | SCN1A, SCN1B, SCN10A | LMNA 1139/4885HPGD 593/4885CYP2C9 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.